What is Moderna's cash & equivalents?

Moderna (MRNA) reported cash & equivalents of $1.91B in Q1 2026.

How has Moderna's cash & equivalents changed year-over-year?

Moderna's cash & equivalents increased by 17.4% year-over-year, from $1.63B to $1.91B.

What is the long-term trend for Moderna's cash & equivalents?

Over 5 years (2020 to 2025), Moderna's cash & equivalents has grown at a -0.3% compound annual growth rate (CAGR), from $2.64B to $2.6B.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Moderna MRNA Cash & Equivalents

Cash & Equivalents at other companies

PfizerPFE

$1.76B+18.8%

NovavaxNVAX

$228.36M-13.3%

ALN

Alnylam PharmaceuticalsALNY

$1.71B+67.5%

Ultragenyx PharmaceuticalRARE

$175M+37.8%

Roivant SciencesROIV

$1.42B+1,411%

Vaxcyte, Inc.PCVX

$262.31M-24.7%

Other financials

Income statement

See full

Revenue$389.0M+260%

Gross profit-$566.0M-3,244%

Operating income-$1.4B-32.2%

Net income-$1.3B-38.3%

EPS (diluted)-$3.40-34.9%

Balance sheet

See full

Total debt$1.3B+71.9%

Total equity$7.4B-26.4%

Total assets$11.5B-9.6%

Cash flow

See full

Operating cash flow-$630.0M+39.2%

CapEx$62.0M-47.0%

Free cash flow-$692.0M+40.0%

Valuation

See full

Market cap$27.09B+115%

Enterprise value$26.51B+120%

P/S12.2×+8.1×

Profitability

See full

Gross margin22.1%-32.0pp

Operating margin-153.3%+67.8pp

Net margin-143.6%+80.2pp

FCF margin-132.4%—

Returns & leverage

See full

Return on equity-36.6%+11.9pp

Debt / equity0.2×+0.1×

Current ratio2.4×-1.8×

Where this comes from

Reported directly by Moderna in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Moderna’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Moderna's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Moderna's cash & equivalents?: Moderna (MRNA) reported cash & equivalents of $1.91B in Q1 2026.
How has Moderna's cash & equivalents changed year-over-year?: Moderna's cash & equivalents increased by 17.4% year-over-year, from $1.63B to $1.91B.
What is the long-term trend for Moderna's cash & equivalents?: Over 5 years (2020 to 2025), Moderna's cash & equivalents has grown at a -0.3% compound annual growth rate (CAGR), from $2.64B to $2.6B.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.